Banner: investors

News Releases

PURE Bioscience Sets Fiscal 2018 Q1 Financial Results Conference Call

November 28, 2017

Food Safety Solutions Update on PURE® Hard Surface and PURE Control® Antimicrobials

SAN DIEGO (Nov. 28, 2017) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on December 14, 2017 the Company will file its Form 10-Q shortly after the close of the market and will host an investor conference call that day at 1:30pm PST (4:30pm EST) to review fiscal 2018 Q1 financial results.

PURE management will also discuss the progress made to commercialize its two antimicrobial SDC-based food safety solutions:

• PURE® Hard Surface disinfectant - The status of ongoing commercialization in restaurant chains (including Chipotle Mexican Grill); processors/manufacturers; and food transportation.

• PURE Control® - The status of ongoing sales and marketing of FDA approved processing aid for fresh produce; the status of the USDA in-plant trials for use as a raw poultry processing aid.

The Participant Dial-In Number for the conference call is 1-631-891-4304. Participants should dial in to the call at least five minutes before 1:30pm PST (4:30pm EST) on December 14, 2017. The call can also be accessed “live” online at http://public.viavid.com/index.php?id=127392.

A replay of the recorded call will be available for 90 days on the Company’s website (http://www.purebio.com/investors/events-presentations/). You can also listen to a replay of the call by dialing 1-844-512-2921 (international participants dial 1-412-317-6671) starting December 14, 2017, at 7:30pm EST through December 21, 2017 at 11:59 pm EST. Please use PIN Number 10003983.

About PURE Bioscience, Inc. 

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements  

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. 

Contacts:

 

Hank Lambert, CEO

Terri MacInnis, VP of IR

Tom Hemingway

PURE Bioscience, Inc.

Bibicoff + MacInnis, Inc.

Redwood Investment Group

619-596-8600 ext.103

818-379-8500

714-978-4425

hlambert@purebio.com

terri@bibimac.com

tomh@redwoodfin.com